tiprankstipranks
Instil Bio reports Q4 EPS (41c), consensus (41c)
The Fly

Instil Bio reports Q4 EPS (41c), consensus (41c)

Q4 Highlights and ancitipated milestones: Instil confirms cash runway beyond 2026 with consolidation of R&D operations to the UK; ITIL-306 phase 1 study in UK anticipated to initiate in 2H’2023; Prioritization of ITIL-306 after discontinuation of ITIL-168 and subsequent consolidation to the UK for manufacturing

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on TIL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles